|
|
Other links at Articles > Pharmacists |
| 4. |
HDL: Keep Aiming High?HDL: Keep Aiming High?
|
|
|
This commentary reflects on the recent halting of the AIM-High study because of the lack of benefits seen with extended-release niacin and what these findings signified about lipid management. br / iMedscape Cardiology/i
|
| 5. |
High-Dose Epirubicin for Breast Cancer Provides No Overall Benefit
|
|
|
High-dose epirubicin with cyclophosphamide provides longer event-free survival than does a low-dose approach as adjuvant chemotherapy for node-positive breast cancer. However, the regimen is more cardiotoxic than is standard oral cyclophosphamide, methotrexate, and fluorouracil (CMF) and the outcome is not superior, according to European researchers. Reuters Health Information
|
|
|
